Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
暂无分享,去创建一个
J. Tabernero | M. Rodríguez | I. Baraibar | J. Ros | F. Salvà | N. Saoudi | E. Élez
[1] J. Tabernero,et al. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers , 2023, Expert review of anticancer therapy.
[2] A. Hauschild,et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice , 2023, Nature Medicine.
[3] M. Fakih,et al. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. , 2023, The oncologist.
[4] L. Wessels,et al. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer , 2023, Nature Medicine.
[5] M. Fassan,et al. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. , 2023, European journal of cancer.
[6] G. Martini,et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. , 2023, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Tabernero,et al. Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer , 2023, Frontiers in Oncology.
[8] D. Jäger,et al. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. , 2023, European journal of cancer.
[9] F. Sinicrope,et al. Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab , 2023, JAMA network open.
[10] Xiao-Quan Yang,et al. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer , 2023, Frontiers in Immunology.
[11] Marieke E. Ijsselsteijn,et al. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects , 2023, Nature.
[12] S. Kopetz,et al. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. Han,et al. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer. , 2023, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] Guolian Zhu,et al. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis , 2022, BMC Gastroenterology.
[15] N. Normanno,et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. G. van den Berg,et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study , 2022, Annals of Oncology.
[17] M. Fakih,et al. 320MO A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC) , 2022, Annals of Oncology.
[18] M. Gonen,et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.
[19] A. El-Khoueiry,et al. LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer , 2022, Annals of Oncology.
[20] P. Cataldo,et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Girard,et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.
[22] K. Ciombor,et al. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. , 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[23] P. Gibbs,et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. , 2022, The Lancet. Oncology.
[24] K. Han,et al. B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy , 2022, Journal of immunotherapy.
[25] C. Burz,et al. Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade , 2022, Life.
[26] E. Van Cutsem,et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Liu,et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. , 2021, The lancet. Gastroenterology & hepatology.
[28] M. Sawyer,et al. Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Mohamed Reda Keddar,et al. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts , 2021, Gastroenterology.
[30] A. Duval,et al. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer , 2021, ESMO open.
[31] A. Cercek,et al. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. , 2021, The New England journal of medicine.
[32] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[33] A. Duval,et al. Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer , 2021, Journal for ImmunoTherapy of Cancer.
[34] D. Berton,et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. , 2021 .
[35] A. Chinnaiyan,et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination , 2021, Nature Medicine.
[36] P. Laurent-Puig,et al. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[37] Siddharth Singh,et al. Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases , 2020, Alimentary pharmacology & therapeutics.
[38] A. Duval,et al. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. , 2020, European journal of cancer.
[39] H. Putter,et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.
[40] P. Gibbs,et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.
[41] C. Tournigand,et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study , 2020, Journal for ImmunoTherapy of Cancer.
[42] Y. Bang,et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.
[43] R. Labianca,et al. Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] D. Tu,et al. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer , 2020, JAMA oncology.
[45] Joon-Oh Park,et al. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer , 2020, Cancer research and treatment : official journal of Korean Cancer Association.
[46] A. Broeks,et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.
[47] J. Larkin,et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] D. Evans,et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer , 2020, Frontiers in Immunology.
[49] L. Plank,et al. Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer , 2019, Clinical and Experimental Medicine.
[50] D. Jäger,et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Malachi Griffith,et al. Best practices for bioinformatic characterization of neoantigens for clinical utility , 2019, Genome Medicine.
[52] Sara R. Selitsky,et al. Alternative tumour-specific antigens , 2019, Nature Reviews Cancer.
[53] I. Matos,et al. Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] J. Ross,et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] P. Ascierto,et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) , 2019, Nature Medicine.
[56] S. Shchegrova,et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.
[57] Ahmet Zehir,et al. Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response , 2019, Science.
[58] Donna Niedzwiecki,et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] M. Ladanyi,et al. Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. , 2019, JCO precision oncology.
[60] Tae Won Kim,et al. Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. , 2019, The Journal of molecular diagnostics : JMD.
[61] A. Duval,et al. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. , 2019, Bulletin du cancer.
[62] P. Ascierto,et al. Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors. , 2019, Journal of Clinical Oncology.
[63] Ji-Hong Liu,et al. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers , 2018, Journal of the National Cancer Institute.
[64] J. Szustakowski,et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.
[65] J. Gartner,et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer , 2018, Nature Medicine.
[66] Benjamin J. Raphael,et al. Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer , 2018, Systems Immuno-Oncology.
[67] B. Neyns,et al. Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. , 2018 .
[68] M. Kloor,et al. High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer , 2018, Oncoimmunology.
[69] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] P. Stephens,et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion , 2017, PloS one.
[71] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[72] D. Kerr,et al. Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1 , 2017, Genome Medicine.
[73] Xianquan Zhang,et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[74] J. Taube,et al. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC , 2017, Cancer Immunology Research.
[75] Jun Gong,et al. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[76] Helen Y Wang,et al. Immune targets and neoantigens for cancer immunotherapy and precision medicine , 2016, Cell Research.
[77] J. Gartner,et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.
[78] P. Park,et al. A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.
[79] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[80] R. Strausberg,et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.
[81] Erik Sahai,et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.
[82] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[83] S. Katz,et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.
[84] Pornpimol Charoentong,et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.
[85] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[86] A. Jemal,et al. Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[87] J. Marshall,et al. A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer , 2013, Annals of surgery.
[88] D. Sargent,et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] Reiko Nishihara,et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. , 2013, Journal of the National Cancer Institute.
[90] Sridhar Ramaswamy,et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] D. Sze,et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. , 2010, Human gene therapy.
[92] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[93] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] R. Houlston,et al. Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[96] B. Leggett,et al. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. , 2002, European journal of cancer.
[97] B. Leggett,et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. , 2001, The American journal of pathology.
[98] T. Smyrk,et al. Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma , 2001, Cancer.
[99] A. Duval,et al. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency , 2019 .
[100] G. Prendergast,et al. Cancer Vaccines: A Brief Overview. , 2016, Methods in molecular biology.
[101] K. Kinzler,et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.